Consequently, combined Gal-9 ab and EGFR-TKI regimens synergistically enhanced cancer therapeutic efficacy over either alone in CT26 or poorly immunogenic LLC tumor-bearing immunocompetent mice, of which the latter were unresponsive to PD-L1 therapy. The gene discussed is LGALS9; the disease is neoplasm.